DOWNSTREAM PROCESSING FEATURED ARTICLES
Making The Switch To Single-Use: Have You Thought Of Everything?
In 2014, Prolong Pharmaceuticals followed through with a decision to build a facility for the scale-up of their lead product, SANGUINATE. As part of this decision, the new facility would not utilize Prolong’s traditional manufacturing process and would instead switch to one that uses single-use technology (SUT) almost exclusively. Chuck Hart, Prolong’s director of manufacturing, recently sat down with me to discuss some areas he feels are sometimes overlooked when switching from traditional stainless steel to SUT.
-
Is There An Enzyme In Your Future? A method for reducing the chemical steps in vitamin C synthesis from six to two underscores the growing importance of enzymes in organic synthesis...
-
Galapagos Receives EUR2.5 Million IWT Grant For IBD Research
Galapagos NV (Euronext: GLPG) announced today that it has been awarded a EUR2.5 million grant from the Flemish agency for Innovation by Science and Technology (IWT) for inflammatory bowel disease (IBD) research and development. The goal of this 2.5-year project is to identify new therapeutic compounds for future treatment of IBD patients.
-
MorphoSys And Heptares Sign Alliance To Develop Antibody Therapeutics Targeting GPCRs
MorphoSys AG (Prime Standard Segment, TecDAX) and UK-based Heptares Therapeutics, the leading GPCR drug discovery and development company, have signed an agreement to discover novel antibody therapeutics targeting G protein-coupled receptors (GPCRs), which are membrane proteins involved in a broad range of biological processes and diseases.
DOWNSTREAM PROCESSING WHITE PAPERS & CASE STUDIES
-
Gemin X Pharmaceuticals: Finding A Drug's Mechanism Of Action
Gemin X, a pharmaceutical company focused on the discovery and development of advanced oncology
therapeutics, approached Metabolon to run a metabolism profile for one of their compounds—GMX1777. -
Optimized Sterile Filtration of Pharmaceutical Solutions
The cost of filtration and separation stages within the production of pharmaceuticals has been increasing along with the increased complexity of final drug products.
-
Biomanufacturing Flexibility
This white paper from BIO-G looks at how to create flexible, agile manufacturing facilities to respond to the current glut of biomanufacturing capacity and industry consolidation. Future proofing these facilities for higher titers and multiple product lines is also explored.
-
Examining Column Reproducibility During Method Development In Clinical Labs
In this study demonstrates how the HSS T3 stationary phase is a reliable stationary phase, as three batches made over a five-year span provide comparable results.
-
Automating Protein Purification Processes Achieves Reliable Results And Reproducibility
ÄKTA start is an easy-to-use, reliable protein purification system. In this application note it is described how Erica, a post-doctoral researcher, used ÄKTA start to purify GST-tagged protein using a predefined method template, a GSTrap FF column, and a Frac30 fraction collector.
-
Important Considerations For Implementing A Single-Use Biomanufacturing Strategy
Recent trends in biomanufacturing technology and the biopharmaceutical market are supporting the increased adoption of single-use (SU) manufacturing systems. On the demand-side, the biopharma industry is focusing on niche and rare diseases with smaller patient populations, resulting in the need for smaller, more agile biomanufacturing capacity. By Jodi M. Zobrist and Nicole W. O'Brien, Ph. D., Gallus Biopharmaceuticals, LLC